SCHEMBL2701033

SCHEMBL2701033

COC(=O)c1cc(N)c(N)cc1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 6/20 0.61
KDM4E B2RXH2 7/20 0.58
CA12 O43570 2/20 0.55
CA1 P00915 2/20 0.55
CA2 P00918 2/20 0.55
CA7 P43166 2/20 0.55
CA9 Q16790 2/20 0.55
CA14 Q9ULX7 2/20 0.55
PDK2 Q15119 1/20 0.55
PDK4 Q16654 1/20 0.55
ALDH1A1 P00352 5/20 0.53
HSD17B10 Q99714 3/20 0.53
MAPT P10636 2/20 0.53
HPGD P15428 2/20 0.53
TSHR P16473 2/20 0.53
ALOX15 P16050 1/20 0.53
CFTR P13569 3/20 0.52
GLA P06280 2/20 0.52
CASP1 P29466 1/20 0.52
CASP7 P55210 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29370673 0.90 GAA (0.59) GAAKDM4ECA12CA1CA2
SCHEMBL18863815 0.90 GAA (0.59) GAAKDM4ECA12CA1CA2
SCHEMBL4758833 0.87 KDM4E (0.73) GAAKDM4ECA12CA1CA2
SCHEMBL22535980 0.87 KDM4E (0.61) GAAKDM4ECA12CA1CA2
SCHEMBL31738319 0.85 KDM4E (0.71) GAAKDM4ECA12CA1CA2
SCHEMBL2721466 0.85 KDM4E (0.56) GAAKDM4ECA12CA1CA2
SCHEMBL4420135 0.85 KDM4E (0.56) GAAKDM4ECA12CA1CA2
SCHEMBL3566173 0.85 GAA (0.68) GAAKDM4ECA12CA1CA2
SCHEMBL3974563 0.85 GAA (0.54) GAAKDM4ECA12CA1CA2
SCHEMBL1109633 0.84 CA12 (0.65) GAAKDM4ECA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120202243-A Thermosetting resin composition, cured film, substrate, and electronic component 捷恩智株式会社 2025-06-24 CN disclosed
US-8519149-B2 Tricyclic compounds as mPGES-1 inhibitors GLENMARK PHARMACEUTICALS S.A. (CH) 2013-08-27 US disclosed
US-8519149-B2 Tricyclic compounds as mPGES-1 inhibitors GLENMARK PHARMACEUTICALS S.A. (CH) 2013-08-27 US disclosed
WO-2012055995-A1 TRICYCLIC COMPOUNDS AS MPGES-1 INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2012-05-03 WO disclosed
WO-2012055995-A1 TRICYCLIC COMPOUNDS AS MPGES-1 INHIBITORS GLENMARK PHARMACEUTICALS S.A. (CH) 2012-05-03 WO disclosed
US-20120108583-A1 Tricyclic Compounds As mPGES-1 Inhibitors GLENMARK PHARMACEUTICALS S.A. (CH) 2012-05-03 US disclosed
US-20120108583-A1 Tricyclic Compounds As mPGES-1 Inhibitors GLENMARK PHARMACEUTICALS S.A. (CH) 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108583-A1 Tricyclic Compounds As mPGES-1 Inhibitors PTGES, PTGS1, PTGIS GAA 1542/4885KDM4E 3359/4885CA12 3505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.